Jetrea: first pharmacological treatment for vitreomacular adhesion

Jetrea (ocriplasmin) is an intravitreal injection for the treatment of vitreomacular traction (VMT), including that associated with macular holes of up to 400 microns diameter.

Treatment with Jetrea in the other eye is not recommended concurrently or within 7 days of the initial injection.
Treatment with Jetrea in the other eye is not recommended concurrently or within 7 days of the initial injection.


Ocriplasmin is a truncated form of human plasmin. It has a proteolytic effect on numerous components of the vitreous body and vitreoretinal interface, including collagen, fibronectin and laminin. It is the abnormal binding of these proteins that can result in vitreomacular adhesion (VMA), leading to VMT.


The safety and efficacy of ocriplasmin was evaluated in two multicentre, randomised, double-blind, phase III studies involving 652 adults with VMT. In an analysis of the combined results, the incidence of VMA resolution at day 28 was significantly higher in patients treated with ocriplasmin than in those given placebo (26.5% vs 10.1%, p<0.001).2

With regard to secondary endpoints, total posterior vitreous detachment at day 28 was more common in the ocriplasmin group than in the placebo group (13.4% vs. 3.7%, p<0.001). Non-surgical closure of macular holes was achieved in 40.6% of ocriplasmin-injected eyes, compared with 10.6% of placebo-injected eyes (p<0.001).2 


  1. Jetrea Summary of Product Characteristics, March 2013.
  2. Stalmans P et al. N Engl J Med 2012; 367: 606–15. 

View Jetrea drug record

Further information: Alcon Laboratories

Follow MIMS on Twitter 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases